Destination 2 – Global Collaboration & Early Success
We are thrilled to share a groundbreaking update from the MR-Linac Consortium: The Royal Marsden has successfully opened recruitment for DESTINATION 2, enrolling over 15 patients into this pioneering trial! As the first Hypothesis Testing Program (HTP) phase II/R-IDEAL 2b study, DESTINATION 2 is redefining prostate cancer treatment. Co-designed by Dr Danny Vesprini, Prof Uulke van der Heide, and Dr Alison …
Read More… from Destination 2 – Global Collaboration & Early Success